Trials / Completed
CompletedNCT06308146
Effect of Bacillus Subtilis ATCC 122264 Supplementation on Gas Symptoms and Quality of Life in Participants With Functional Bloating
Evaluating the Efficacy of Bacillus Subtilis ATCC 122264 on Intestinal Gas Symptoms and Quality of Life in Participants With Functional Bloating: a Randomized, Double-blind, Placebo-controlled, 2-arm Parallel Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Kerry Group P.L.C · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A randomized, double blind, placebo-controlled, 2-arm parallel study to evaluate the efficacy of Bacillus subtillis in providing relief and improving quality of life in participants suffering from functional abdominal bloating/distension when administered for a period of 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Bacillus subtilis ATCC 122264 | One capsule (5 billion CFU) per day for 8 weeks. |
| DIETARY_SUPPLEMENT | Placebo | One capsule per day for 8 weeks. |
Timeline
- Start date
- 2022-04-21
- Primary completion
- 2022-10-11
- Completion
- 2022-10-11
- First posted
- 2024-03-13
- Last updated
- 2024-03-15
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06308146. Inclusion in this directory is not an endorsement.